美国Arcutis Biotherapeutics获得加拿大卫生部批准使用ZORYVE Foam 0.3%的新型斑疹性皮肤炎治疗药物. Arcutis Biotherapeutics receives Health Canada approval for a new seborrheic dermatitis treatment, ZORYVE Foam 0.3%.

对于ZORYVE (Roflumilast) 泡0. 3%,用于治疗9岁及以上的小皮肤炎,Arcutis Biotherapeutics已获得加拿大卫生部的批准. Arcutis Biotherapeutics has received Health Canada approval for ZORYVE (Roflumilast) Foam 0.3%, a treatment for seborrheic dermatitis in individuals aged 9 and older. 这是20多年来首次获得批准的具有独特作用机制的新型局部治疗. This is the first new topical treatment with a unique mechanism of action approved in over 20 years. 这种泡沫不含类固醇，旨在使超过 200 万患有这种疾病的加拿大人受益。 The foam is steroid-free and aims to benefit over 2 million Canadians with the condition. 这一批准使Arcutis不断扩大的皮肤学投资组合得到补充。 This approval adds to Arcutis’ expanding dermatology portfolio.